Doximity, Inc. (NASDAQ:DOCS) Shares Sold by Blair William & Co. IL

Key Points

• Blair William & Co. IL reduced its stake in Doximity, Inc. by 39.7%, owning 16,091 shares valued at $934,000 after selling 10,592 shares in the first quarter.
• Director Timothy S. Cabral sold 10,000 shares at an average price of $60.00, a decrease of 61.12% in his holdings, while insider sales totaled $1.8 million in the last quarter.
• Doximity's stock currently has an average price target of $66.68, with analysts rating it as a "Moderate Buy" after the company's earnings beat expectations, reporting $0.36 earnings per share compared to an estimate of $0.31.

Blair William & Co. IL cut its holdings in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 39.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,091 shares of the company's stock after selling 10,592 shares during the quarter. Blair William & Co. IL's holdings in Doximity were worth $934,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of DOCS. VSM Wealth Advisory LLC acquired a new position in Doximity in the 1st quarter valued at about $29,000. Allworth Financial LP increased its position in shares of Doximity by 104.0% in the 1st quarter. Allworth Financial LP now owns 563 shares of the company's stock valued at $32,000 after purchasing an additional 287 shares during the last quarter. Spire Wealth Management increased its position in shares of Doximity by 73.2% in the 1st quarter. Spire Wealth Management now owns 615 shares of the company's stock valued at $36,000 after purchasing an additional 260 shares during the last quarter. Kapitalo Investimentos Ltda acquired a new position in shares of Doximity in the 4th quarter valued at $50,000. Finally, Cullen Frost Bankers Inc. acquired a new position in shares of Doximity in the 1st quarter valued at $64,000. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on DOCS shares. Wells Fargo & Company increased their price target on shares of Doximity from $55.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Monday, August 4th. William Blair restated an "outperform" rating on shares of Doximity in a research report on Friday, May 16th. Mizuho dropped their target price on shares of Doximity from $65.00 to $60.00 and set a "neutral" rating for the company in a report on Friday, May 16th. The Goldman Sachs Group set a $50.00 price target on shares of Doximity and gave the stock a "neutral" rating in a research note on Wednesday, May 21st. Finally, JPMorgan Chase & Co. decreased their price target on shares of Doximity from $63.00 to $60.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 27th. Ten analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Doximity presently has an average rating of "Moderate Buy" and an average price target of $66.68.

Insiders Place Their Bets

In other Doximity news, Director Timothy S. Cabral sold 10,000 shares of the business's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. Following the sale, the director owned 6,360 shares in the company, valued at approximately $381,600. The trade was a 61.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Regina M. Benjamin sold 5,000 shares of the business's stock in a transaction dated Friday, July 11th. The stock was sold at an average price of $60.04, for a total value of $300,200.00. Following the sale, the director owned 16,618 shares in the company, valued at approximately $997,744.72. The trade was a 23.13% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 31,000 shares of company stock worth $1,825,940. Company insiders own 31.30% of the company's stock.

Doximity Stock Up 13.9%

DOCS stock opened at $66.71 on Friday. The company has a market capitalization of $12.53 billion, a P/E ratio of 66.71, a PEG ratio of 4.10 and a beta of 1.36. The company has a 50-day simple moving average of $59.21 and a 200 day simple moving average of $60.03. Doximity, Inc. has a fifty-two week low of $32.58 and a fifty-two week high of $85.21.

Doximity (NASDAQ:DOCS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same period in the prior year, the business posted $0.28 earnings per share. The firm's quarterly revenue was up 15.2% compared to the same quarter last year. Equities analysts anticipate that Doximity, Inc. will post 0.99 EPS for the current year.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.